Expert opinion on current issues and challenges in irritable bowel syndrome
DOI:
https://doi.org/10.18203/2349-3933.ijam20241640Keywords:
IBS, Gastrointestinal disorder, Rome criteria, Biomarkers, Antispasmodics, Pinaverium bromideAbstract
Irritable bowel syndrome (IBS) is a widely prevalent functional gastrointestinal disorder characterized by symptoms such as abdominal pain, irregular bowel movements, and bloating, which significantly impact affected individuals' well-being. The increasing prevalence of IBS in India places a substantial burden on clinical practice. Although diagnostic criteria, such as the commonly used Rome IV criteria, have shown reasonable sensitivity, the diagnosis of IBS remains a nuanced and culturally influenced process. This comprehensive review systematically examines current challenges surrounding IBS prevalence, diagnostic intricacies, and the complex pathophysiology involving visceral hypersensitivity. The review highlights the imperative for noninvasive biomarkers to augment diagnostic precision and emphasizes on following a holistic approach to IBS management as advocated by Indian guidelines. This approach integrates dietary modifications, antispasmodic medications, psychological therapy, and yoga, with specific emphasis on tailoring treatments to individual IBS subtypes. Among antispasmodic drugs, pinaverium bromide because of its unique mechanism of action as a calcium channel antagonist within the gastrointestinal tract has shown promise in alleviating IBS symptoms.
References
Ikechi R, Fischer BD, DeSipio J, Phadtare S. Irritable bowel syndrome: Clinical manifestations, dietary influences, and management. Healthcare (Basel). 2017;5(2):21.
Nagaonkar SN, Singh VS, Kangule DT, Sadhanala SA. A study of prevalence and determinants of irritable bowel syndrome in an urban slum community in Mumbai. J Datta Meghe Inst Med Sci Univ. 2018;13(2):87-90.
Deiteren A, de Wit A, Linden LV, De Man JG, Pelckmans PA, DeWinter BY. Irritable bowel syndrome and visceral hypersensitivity: Risk factors and pathophysiological mechanisms. Acta Gastroenterol Belg. 2016;79(1):29-38.
Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2(6138):653-4.
Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II: The functional gastrointestinal disorders: Diagnosis, pathophysiology, and treatment: A multinational consensus. 2nd ed. McLean, VA: Degnon Associates. 2000.
Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2012;25(1):46-52.
Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759-73.
Gwee KA, Bak YT, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, et al. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25(7):1189-205.
Ghoshal UC, Abraham P, Bhatia SJ, Misra SP, Choudhuri G, Biswas KD, et al. Comparison of Manning, Rome I, II, and III, and Asian diagnostic criteria: report of the Multicentric Indian Irritable Bowel Syndrome (MIIBS) study. Indian J Gastroenterol. 2013;32(6):369-75.
Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut. 2002;51(1):i67-71.
Marynowski M, Likońska A, Zatorski H, Fichna J. Role of environmental pollution in irritable bowel syndrome. World J Gastroenterol. 2015;21(40):11371-8.
Plavšić I, Hauser G, Tkalčić M, Pletikosić S, Salkić N. Diagnosis of irritable bowel syndrome: Role of potential biomarkers. Gastroenterol Res Pract. 2015;2015:490183.
Morales W, Rezaie A, Barlow G, Pimentel M. Second-generation biomarker testing for irritable bowel syndrome using plasma anti-CdtB and anti-vinculin levels. Dig Dis Sci. 2019;64(11):3115-21.
Linsalata M, Riezzo G, D'Attoma B, Clemente C, Orlando A, Russo F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study. BMC Gastroenterol. 2018;18(1):167.
Ghoshal UC, Sachdeva S, Pratap N, Karyampudi A, Mustafa U, Abraham P, et al. Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology. Indian J Gastroenterol. 2023;42(2):249-73.
Annaházi A, Róka R, Rosztóczy A, Wittmann T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031-43.
Bor S, Lehert P, Chalbaud A, Tack J. Efficacy of pinaverium bromide in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211033740.
Zheng L, Lai Y, Lu W, Li B, Fan H, Sun Y, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clin Gastroenterol Hepatol. 2015;13(7):1285-92.
Jayanthi V, Malathi S, Ramathilakam B, Dinakaran N, Balasubramanian V, Mathew S. Role of pinaverium bromide in south Indian patients with irritable bowel syndrome. J Assoc Physicians India. 1998;46(4):369-71.
Zheng L, Lu W, Xiao Q, Lai Y, Fan H, Sun Y, et al. Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial. Sci Rep. 2021;11(1):13894.
